HeartFlow's FDA-cleared AI Plaque Analysis is revolutionizing heart care! It achieves 95% accuracy against the invasive gold standard and drives personalized treatment plans, changing management for up to 66% of patients. This non-invasive tool offers superior long-term risk prediction and has secured national payer coverage (including Cigna and Medicare) for broader patient access.
New data highlight long-term benefits of HeartFlow's AI-based CAD evaluations. Superior predictor of long-term adverse cardiovascular events.
New data highlight long-term benefits of HeartFlow's AI-based CAD evaluations. Superior predictor of long-term adverse cardiovascular events.